[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
|
[3] |
Chan MV, Huo YR, Trieu N, et al. Noncontrast MRI for hepatocellular carcinoma detection: A systematic review and Meta-analysis - A potential surveillance tool?[J]. Clin Gastroenterol Hepatol, 2021: S1542-3565(21)00215-9.
|
[4] |
Wu S, Zeng N, Sun F, et al. Hepatocellular carcinoma prediction models in chronic hepatitis B: A systematic review of 14 models and external validation[J]. Clin Gastroenterol Hepatol, 2021: S1542-3565(21)00219-6.
|
[5] |
Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China[J]. JAMA Surg, 2019, 154(3): 209-217.
|
[6] |
Raoul JL, Edeline J. Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere[J]. Lancet Oncol, 2020, 21(4): 479-481.
|
[7] |
Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states[J]. Liver Int, 2021, 41(5): 1097-1104.
|
[8] |
Jin S, Tan S, Peng W, et al. Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: A systematic review and Meta-analysis[J]. World J Surg Oncol, 2020, 18(1): 199.
|
[9] |
Zheng X, Chen L, Zhou Y, et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling[J]. Mol Cancer, 2019, 18(1): 47.
|
[10] |
Wesselhoeft RA, Kowalski PS, Parker-Hale FC, et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo[J]. Mol Cell, 2019, 74(3): 508-520.
|
[11] |
Wei Y, Chen X, Liang C, et al. A noncoding regulatory RNAs network driven by Circ-CDYL acts specifically in the early stages hepatocellular carcinoma[J]. Hepatology, 2020, 71(1): 130-147.
|
[12] |
Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer[J]. Cell, 2019, 176(4): 869-881, e13.
|
[13] |
Liang WC, Wong CW, Liang PP, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway[J]. Genome Biol, 2019, 20(1): 84.
|
[14] |
Wang L, Long H, Zheng Q, et al. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression[J]. Mol Cancer, 2019, 18(1): 119.
|
[15] |
Yu J, Xu QG, Wang ZG, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma[J]. J Hepatol, 2018, 68(6): 1214-1227.
|
[16] |
Liu F, Zhang J, Qin L, et al. Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation[J]. Aging (Albany NY), 2018, 10(12): 3806-3820.
|
[17] |
Zhang T, Li M, Lu H, et al. Up-regulation of circEIF6 contributes to pancreatic cancer development through targeting miR-557/SLC7A11/PI3K/AKT signaling[J]. Cancer Manag Res, 2021, 13: 247-258.
|
[18] |
Zhang Y, Liu H, Li W, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630[J]. Aging (Albany NY), 2017, 9(6): 1585-1594.
|
[19] |
Wang L, Shen J, Jiang Y. Circ_0027599/PHDLA1 suppresses gastric cancer progression by sponging miR-101-3p.1[J]. Cell Biosci, 2018, 8: 58.
|